Literature DB >> 8821778

The effect of 5-lipoxygenase inhibition on Ascaris antigen (Ag)-induced responses in atopic monkeys.

C R Turner1, W B Smith, C J Andresen, J F Eggler, J W Watson.   

Abstract

The effects of two 5-lipoxygenase (5LO) inhibitors, ZD2138 or Zileuton, on acute, inflammatory responses to aerosolized Ascaris suum (Ag) were determined in atopic Macaca fascicularis monkeys. Monkeys (n = 6 each group) were dosed with vehicle, 3 or 10 mg/kg ZD2138, or 30 mg/kg Zileuton (p.o.). Both ZD2138 or Zileuton significantly inhibited ex vivo LTB4 production in Ca2+ ionophore-stimulated whole blood from these same monkeys (n = 6 each group) by 45.5% (3 mg/kg ZD2138), 82.5% (10 mg/kg ZD2138) and 84.3% (30 mg/kg Zileuton). ZD2138 (10 mg/kg) reduced bronchoalveolar lavage (BAL) LTE4 levels (65.1% inhibition), BAL neutrophils (88.9% inhibition), and IL-6 (54.0% inhibition) 4h post Ag. Zileuton inhibited these responses and also reduced BAL levels of IL-8 (73.4% inhibition). A second study was performed to evaluate the effects of ZD2138 on chronic Ag-induced responses. Treatment with ZD2138 did not prevent pulmonary inflammation or the development of airway hyperresponsiveness (AHR). Based upon these results, 5LO inhibition significantly reduced ex vivo LTB4 and in vivo LTE4 production as well as several acute inflammatory responses to Ag in the lung. However, ZD2138 did not inhibit more chronic responses following multiple Ag exposure.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8821778     DOI: 10.1007/bf02263504

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  20 in total

1.  Antigen-induced acute and late-phase responses in primates.

Authors:  R H Gundel; C D Wegner; L G Letts
Journal:  Am Rev Respir Dis       Date:  1992-08

2.  Repeated antigen inhalation results in a prolonged airway eosinophilia and airway hyperresponsiveness in primates.

Authors:  R H Gundel; M E Gerritsen; G J Gleich; C D Wegner
Journal:  J Appl Physiol (1985)       Date:  1990-02

3.  Inhibition of human mononuclear cell proliferation, interleukin synthesis, mRNA for IL-2, IL-6, and leukotriene B4 synthesis by a lipoxygenase inhibitor.

Authors:  D Atluru; S Gudapaty; M P O'Donnell; G E Woloschak
Journal:  J Leukoc Biol       Date:  1993-10       Impact factor: 4.962

4.  Effects of rolipram on responses to acute and chronic antigen exposure in monkeys.

Authors:  C R Turner; C J Andresen; W B Smith; J W Watson
Journal:  Am J Respir Crit Care Med       Date:  1994-05       Impact factor: 21.405

5.  Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.

Authors:  R M McMillan; K E Spruce; G C Crawley; E R Walker; S J Foster
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

6.  Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes.

Authors:  A W Ford-Hutchinson; M A Bray; M V Doig; M E Shipley; M J Smith
Journal:  Nature       Date:  1980-07-17       Impact factor: 49.962

Review 7.  Mechanisms of eosinophil recruitment.

Authors:  M B Resnick; P F Weller
Journal:  Am J Respir Cell Mol Biol       Date:  1993-04       Impact factor: 6.914

8.  Asthma and increases in nonallergic bronchial responsiveness from seasonal pollen exposure.

Authors:  L P Boulet; A Cartier; N C Thomson; R S Roberts; J Dolovich; F E Hargreave
Journal:  J Allergy Clin Immunol       Date:  1983-04       Impact factor: 10.793

9.  Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation.

Authors:  P Bradding; I H Feather; S Wilson; P G Bardin; C H Heusser; S T Holgate; P H Howarth
Journal:  J Immunol       Date:  1993-10-01       Impact factor: 5.422

10.  Leukotriene D4 receptor antagonism reduces airway hyperresponsiveness in monkeys.

Authors:  C R Turner; W B Smith; C J Andresen; A C Swindell; J W Watson
Journal:  Pulm Pharmacol       Date:  1994-02
View more
  2 in total

1.  Molecular pharmacological profile of a novel thiazolinone-based direct and selective 5-lipoxygenase inhibitor.

Authors:  B Hofmann; C B Rödl; A S Kahnt; T J Maier; A A Michel; M Hoffmann; O Rau; K Awwad; M Pellowska; M Wurglics; M Wacker; A Zivković; I Fleming; M Schubert-Zsilavecz; H Stark; G Schneider; D Steinhilber
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610.

Authors:  Lutz Fischer; Dieter Steinhilber; Oliver Werz
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.